세계의 혈구탐식성림프조직구증식증 치료 시장(2023-2030년)

Overview

The global hemophagocytic lymphohistiocytosis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Hemophagocytic lymphohistiocytosis (HLH), an uncommon illness, primarily affects babies and young children. The condition typically passes down to children. Adults can develop HLH from a wide range of illnesses, such as cancer and infections.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or technologies and boost the global hemophagocytic lymphohistiocytosis treatment market. The respective innovative products includes the use of novel drugs such as monoclonal antibodies for better treatment.

Market Dynamics: Drivers & Restraints

Growing acquisition and partnerships among key players

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for Hemophagocytic Lymphohistiocytosis Treatment owing to its positive outcomes in research. Various acquisitions and product launches among key players will be a crucial factor driving the growth of the market.

On March 9, 2023, F-star Therapeutics, Inc., a biopharmaceutical company in the clinical stage that invented bispecific antibodies in immunotherapy, has been successfully acquired by invoX Pharma Limited, a fully-owned subsidiary based in U.K. of Sino Biopharmaceutical Limited ("Sino Biopharm"), for a total approximate cash valuation of $161 million (or $7.12 per share).

According to Canadian Journal of Health Technologies 2022, Anakinra may lower 28-day mortality and the probability of death in people with hemophagocytic lymphohistiocytosis (HLH), according to data from one retrospective cohort research (included in one comprehensive review).

Furthermore, the rising utilization of novel technologies or drugs for the management of hemophagocytic lymphohistIocytosis. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the hemophagocytic lymphohistiocytosis treatments market.

Side effects associated with the medication

High blood pressure, infections, infusion-related adverse responses (fever, redness, rash, sweating), low blood potassium, fever, and constipation are typical side effects. Fever, weakness, coughing, trouble breathing, diarrhea, stomach discomfort, chills, sweating, burning sensations while urinating, and more frequent urination are symptoms of a serious infection. These were the few commonly reported adverse events in the key trial. Gamifant users who experienced less than 10% of these additional graded adverse effects (all grades) included vomiting, acute renal injury, asthenia, dyspnea, bradycardia, gastrointestinal bleeding, epistaxis, and peripheral edema.

For more details on this report - Request for Sample

Segment Analysis

The global hemophagocytic lymphohistiocytosis treatment market is segmented based on type, medication, route of administration, distribution channel and region.

Biologics segment accounted for approximately 38% of market share

Monoclonal antibodies, immune modulators, growth factors, vaccinations, and items made from human blood and plasma all fall within the broad category of biological medicines. Biological treatments have the potential to worsen or possibly start HLH. An interferon gamma (IFN) blocking monoclonal antibody is what Gamifant (emapalumab) is. It reduces inflammation by inhibiting an immune system molecule called interferon gamma. The inflammation-related symptoms of primary HLH are lessened as a result.

On March 7, 2023, the enrollment in the ongoing pivotal Phase 3 research of Tadekinig alfa by AB2 Bio Ltd., a biotechnology business dedicated to discovering novel medicines for the treatment of serious systemic autoinflammatory illnesses and disorders induced by IL-18, has been completed. The goal of the trial is to demonstrate the safety and efficacy of Tadekinig alfa (r-hIL-18BP) for the management of primary monogenic IL-18 led HLH, an extremely rare and fatal illness that primarily affects children and lacks any approved treatments. Topline findings are expected in the second half of 2023, according to AB2 Bio.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for hemophagocytic lymphohistiocytosis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for hemophagocytic lymphohistiocytosis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different type of devices for management, and increase in pharmaceutical or medical device business establishment across the region are also contributing to the growth of hemophagocytic lymphohistiocytosis treatment market share of this region. The market in this area is growing as people become more aware of various novel innovative drugs such as emapalumab. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global hemophagocytic lymphohistiocytosis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for hemophagocytic lymphohistiocytosis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating hemophagocytic lymphohistiocytosis treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global hemophagocytic lymphohistiocytosis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for hemophagocytic lymphohistiocytosis treatment. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global hemophagocytic lymphohistiocytosis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like tadekinig alfa and other programs for management of hemophagocytic lymphohistiocytosis.

Key Developments

• On January 30, 2023, with the Guangzhou Development Zone Administrative Committee, Sino Biopharm plus its affiliate CTTQ signed a framework agreement to invest in the creation of a regional Southern base and an international innovation hub in the area. By gradually integrating R&D, manufacturing, sales, and marketing services, the Guangzhou invention center will grow to be Sino Biopharm's "second engine" and help the company reach its revenue goal of HK$100 billion by 2030.
• On December 10, 2022, According to American Society of Hematology, patients in the phase II study got dexamethasone and ruxolitinib (15 mg twice daily) over an eight-week period. Janus kinase (JAK) inhibitor which is orally administered is called roxolitinib inhibits JAK enzymes along with downstream cytokines that are active in HLH, however some JAK-pathway-activated cytokines can lead to glucocorticoid resistance. Ruxolitinib may be able to help reverse this, according to in vitro and in vivo experiments. The medication was well tolerated, according to researchers, and no patients needed dose adjustments.

Competitive Landscape

The major global players in the market include: Swedish Orphan Biovitrum, Incyte, Sanofi, AB2 Bio Ltd., Genentech, Inc., Pfizer Inc., Viatris Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited and Merck KGaA.

Why Purchase the Report?

• To visualize the global hemophagocytic lymphohistiocytosis treatment market segmentation based on type, medication, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hemophagocytic lymphohistiocytosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hemophagocytic lymphohistiocytosis treatment market report would provide approximately 69 tables, 67 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Medication
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing acquisition and partnerships among key players
    • 4.1.1.2. Rising technological advancements and developments
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with the medication
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. SWOT Analysis
• 5.6. Patent Analysis
• 5.7. Russia-Ukraine War Impact Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Familial Hemophagocytic Lymphohistiocystosis*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Acquired Hemophagocytic Lymphohistiocystosis

8. By Medication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 8.1.2. Market Attractiveness Index, By Medication
• 8.2. Antineoplastic Agents*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Etoposide (Toposar, VePesid)
  • 8.2.4. Methotrexate (Trexall)
  • 8.2.5. Cisplatin
• 8.3. Corticosteroids
  • 8.3.1. Dexamethasone (Decadron, Hexadrol)
  • 8.3.2. Methylprednisolone
• 8.4. Immunosuppressant Agents
  • 8.4.1. Cyclosporine (Sandimmune, Neoral)
  • 8.4.2. Rituximab (Rituxan)
• 8.5. Biologics
  • 8.5.1. Emapalumab (Gamifant, emapalumab-lzsg)
  • 8.5.2. Alemtuzumab (Campath)
  • 8.5.3. Tadekinig Alfa
• 8.6. Immune Globulins

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Parenteral

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Swedish Orphan Biovitrum*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Incyte
• 13.3. Sanofi
• 13.4. AB2 Bio Ltd.
• 13.5. Genentech, Inc.
• 13.6. Pfizer Inc.
• 13.7. Viatris Inc.
• 13.8. Bristol-Myers Squibb Company
• 13.9. Takeda Pharmaceutical Company Limited
• 13.10. Merck KGaA

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us